⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630791 | 0.87 | ALDH1A1 (0.62) | — | |
| SCHEMBL24023361 | 0.84 | ALDH1A1 (0.58) | — | |
| SCHEMBL27019720 | 0.84 | ALDH1A1 (0.58) | — | |
| SCHEMBL290725 | 0.81 | — | — | |
| Clomethiazole SCHEMBL35223 | 0.80 | — | — | |
| SCHEMBL8011142 | 0.80 | — | — | |
| SCHEMBL5871890 | 0.80 | — | — | |
| SCHEMBL259480 | 0.80 | — | — | |
| SCHEMBL3091821 | 0.80 | — | — | |
| SCHEMBL2642153 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024293-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | REVIVO THERAPEUTICS (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11180457-B2 | Fluorine-containing ether compound, lubricant for magnetic recording medium, and magnetic recording medium | SHOWA DENKO K. K. (JP) | 2021-11-23 | — | — | US | disclosed |
| EP-2865669-B1 | NOVEL REBAMIPIDE PRODRUG, METHOD FOR PRODUCING SAME, AND USAGE THEREOF | SAMJIN PHARM CO LTD (KR) | 2021-04-28 | — | — | EP | disclosed |
| US-20200283392-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | SHOWA DENKO K.K. (JP) | 2020-09-10 | — | — | US | disclosed |
| US-20190084911-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | SHOWA DENKO K.K. (JP) | 2019-03-21 | — | — | US | disclosed |
| EP-3339308-A1 | RADIOISOTOPE FLUORINE-18 SUBSTITUTED THIAMINE, SYNTHESIS METHOD THEREFOR, AND APPLICATIONS THEREOF | Zhongshan Hospital Fudan University (CN) | 2018-06-27 | — | — | EP | disclosed |
| US-20170044118-A1 | SALT COMPOUND | SGC PHARMA, INC. (IN) | 2017-02-16 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20090170853-A1 | 4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent (hepatocellular cancer, colorectal cancer or non-small cell lung cancer) | BRISTOL-MYERS SQUIBB COMPANY | 2009-07-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7521450-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7393827-B2 | Pharmaceutical compositions and methods for restoring β-cell mass and function | DIAKINE THERAPEUTICS, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070299075-A1 | e.g. 1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-4-(aminosulfonyl)aminobutan-2-ol; inhibit the tyrosine kinase activity of endothelial and fibroblast growth factors receptors; angiogenesis inhibitor; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-27 | — | — | US | disclosed |
| US-7265113-B2 | Inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-04 | — | — | US | disclosed |